Older Breast Cancer Patients: Risk for Cognitive Decline
NCT03451383
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how genetic polymorphisms, inflammatory biomarkers, sleep and physical measures moderate cognitive outcomes.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cancer, Breast
- Age-related Cognitive Decline
- Cognitive Decline
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 60 to 105 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Georgetown University
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
District of Columbia · 1
- Georgetown University · Washington D.C., DC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.